Observational study on medical cannabis use in children
Real World Evidence on the Use of Medical Cannabis in Pediatrics: A Prospective Observational Study
This study is looking at how medical cannabis affects children aged 3 to 17 with various health issues, including cancer, by tracking their pain, sleep, mood, behavior, and seizures over two years.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 3 Years to 17 Years |
| Sex | All |
| Sponsor | University of Manitoba Academic / other |
| Locations | 1 site (Winnipeg, Manitoba) |
| Trial ID | NCT05863910 on ClinicalTrials.gov |
What this trial studies
This observational study, CAN-RWE, follows 500 pediatric patients aged 3 to 17 years across Canada who have received authorizations for medical cannabis. Over a period of two years, participants will report on various outcome measures including pain, sleep, mood, behavior, and seizure management. Data will be collected at multiple intervals to assess the effectiveness and safety of medical cannabis in managing symptoms related to cancer and other conditions. The study aims to provide real-world evidence on the impact of medical cannabis in pediatric populations.
Who should consider this trial
Good fit: Ideal candidates are children aged 3 to 17 years who have a valid medical cannabis authorization for specific conditions such as pain, sleep issues, mood disorders, behavior problems, seizures, or cancer-related symptoms.
Not a fit: Patients who are using cannabis recreationally or do not have a medical cannabis authorization from a healthcare provider will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the effectiveness of medical cannabis for managing symptoms in children with serious health conditions.
How similar studies have performed: While the use of medical cannabis in pediatrics is a growing area of interest, this study aims to provide real-world evidence, making it a novel approach in this specific context.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 3 to 17 years * have a medical document provided by a prescribing health care practitioner (i.e. physician, nurse practitioner, etc.) for the use of medical cannabis * medical cannabis is authorized for pain, sleep, mood, behaviour, seizures, cancer or cancer-treatment related symptom management * ability to respond to electronic questionnaires in English Exclusion Criteria: * individuals using cannabis for medical purposes without a medical cannabis authorization from a health care provider * those only using cannabis recreationally
Where this trial is running
Winnipeg, Manitoba
- U Manitoba — Winnipeg, Manitoba, Canada (Recruiting)
Study contacts
- Principal investigator: Sapna Oberoi, MD — University of Manitoba
- Study coordinator: Lauren E Kelly, PhD
- Email: lauren.kelly@umanitoba.ca
- Phone: 2042723149
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.